Il commercio parallelo di farmaci tra libera circolazione delle merci e prospettive evolutive nell’ambito della nuova Strategia farmaceutica per l’Europa

Parallel trade of pharmaceuticals is one of the most contended issues emerging from this industrial sector, which requires to strike a sensitive balance between the fundamental tenets of the internal market (particularly the free movement of goods), the Member States’ competence in regulating the prices of medicines and the conflicting interests of manufacturers and patients. Against this background, this Insight addresses the decision rendered on 25 November 2021 by the Court of Justice in Case C-488/20 Delfarma ECLI:EU:C:2021:956 and further elaborates some prospective considerations on parallel trade in the light of the problem of medicines shortages in the European Union, considering the recent initiatives falling under the new Pharmaceutical Strategy for Europe.